Advertisement

ß-Rezeptor-Subtypen beim Menschen

  • G. Vauquelin

Zusammenfassung

Bereits zu Beginn dieses Jahrhunderts wies der Befund, daß Mutterkornalkaloide nur gewisse Effekte von Adrenalin blockieren konnten, auf das Konzept verschiedener adrenerger Rezeptorsubtypen hin. Diese Vorstellung wurde jedoch ignoriert, bis Ahlquist 1948 nachwies, daß es 2 Gruppen adrenerger Rezeptoren gibt, die jeweils ein spezifisches pharmakologisches Profil aufweisen [1]. Die α-adrenergen Rezeptoren wurden mit der Mehrzahl der erregenden Wirkungen assoziiert (z. B. Vasokonstriktion und Kontraktion der glatten Uterusmuskulatur) der ß-adrenerge Rezeptor wurde mit der Mehrzahl der hemmenden Wirkungen (z. B. Vasodilatation und Relaxation der glatten Uterus- und Bronchialmuskulatur) und einer wichtigen erregenden Wirkung (Myokardstimulation) in Verbindung gebracht.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153: 586–600.PubMedGoogle Scholar
  2. 2.
    Shanks RG (1984) The discovery of β-adrenoceptor blocking drugs. Trends Pharmacol Sci 5: 405–409.CrossRefGoogle Scholar
  3. 3.
    Black JW, Stephenson JS (1962) Pharmacolog of a new beta-adrenergic receptor blocking compound. Lancet: 311–314.Google Scholar
  4. 4.
    Lands AM, Luduena FP, Brown TG (1967) Differentiation of receptors activated by sympathomimetic amines. Nature 214: 597–598.PubMedCrossRefGoogle Scholar
  5. 5.
    Summers RJ, Molenaar P, Stephenson JA (1987) Autoradiographic localisation of receptors in the cardiovascular system. Trends Pharmacol Sci 8: 272–276.CrossRefGoogle Scholar
  6. 6.
    Abrahamsson T, Ek B, Nerme V (1988) The β1 and β2-receptor affinity of atenolol and metoprolol. Biochem Pharmacol 37: 203–208.PubMedCrossRefGoogle Scholar
  7. 7.
    Harron WG, Balnave K, Kinney CD, Wilson R, Russell CJ, Shanks RG (1981) Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol and metoprolol. Clin Pharmacol Ther 29: 295–302.PubMedCrossRefGoogle Scholar
  8. 8.
    Buxton BF, Jones CR, Molenaar P, Summers RJ (1987) Characterisation and autoradiographic localization of β-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol 92: 299–310.PubMedGoogle Scholar
  9. 9.
    Chidsey CA, Braunwald E (1966) Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev 18: 685–700.PubMedGoogle Scholar
  10. 10.
    Robison GA, Butcher RW, Sutherland EW (1971) Cyclic AMP. Academic Press, New York.Google Scholar
  11. 11.
    Singer JJ, Nicholson GL (1972) The fluid mosaic model of the structure of cell membranes: cell membranes are viewed as two-dimensional solutions oforiented globular proteins and lipids. Science 175: 720–731.PubMedCrossRefGoogle Scholar
  12. 12.
    Vauquelin G, Geynet P, Hanoune J, Strosberg AD (1977) Isolation of adenylate cyclase free β- adrenergic receptor from turkey erythrocyte membranes by affinity chromatography, Proc. Natl. Acad. Sci. USA 74: 3710–3714.PubMedCrossRefGoogle Scholar
  13. 13.
    Dixon RAF, Koblika BK, Strader DJ, Benovic JL, Dolman HG, Frielle T, Bolanowski MA, Bennet CD, Rands E, Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD (1986) Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin, Nature 231: 75–79.CrossRefGoogle Scholar
  14. 14.
    Ostrowski J, Kjelsberg MA, Caron MG, Lefkowitz RJ (1992) Mutagenesis of the β2-adrenergic receptor: how structure elucidates function. Ann Rev Pharmacol Toxicol 32: 167–183.CrossRefGoogle Scholar
  15. 15.
    Emorine LJ, Marullo S, Briend-Sutren M-M, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (1989) Molecular characterization of the human β-adrenergic receptor. Science 245: 1118–1120.PubMedCrossRefGoogle Scholar
  16. 16.
    Harms HH, Zaagsma J, Van Der Wal B (1974) β-adrenoceptor studies III. On the p-adreno- ceptors in rat adipose tissue. Eur J Pharmacol 25: 87–91.Google Scholar
  17. 17.
    Langin D, Portillo MP, Saulnier-Blache J-S, Lafontan M (1991) Coexistence of three β-adrenergic receptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199: 291–301.PubMedCrossRefGoogle Scholar
  18. 18.
    Marcus C, Ehren H, Bolme P, Arner P (1988) Regulation of lipolysis during the neonatal period: importance of thyrotropin. J Clin Invest 82: 1793–1797.PubMedCrossRefGoogle Scholar
  19. 19.
    Arner P (1992) Adrenergic receptor function in fat cells. Am J Clin Nutr 55: 228s–236s.PubMedGoogle Scholar
  20. 20.
    Van Liefde I, Witzenburg A van, Vauquelin G (1992) Multiple P-adrenergic receptor subclasses mediate the I-isoproterenol-induced lypolytic response in rat adipocytes. J Pharmacol Exp Ther 262: 552–558.PubMedGoogle Scholar
  21. 21.
    Van Liefde I, Van Ermen A, Vauquelin G (1994) No functional atypical β-adrenergic receptors in human omental adipocytes. Life Sci 54: 209–214.Google Scholar
  22. 22.
    Mauriege P, De Pergola G, Berlan M, Lafontan M (1988) Human fat cell β-adrenergic receptors: β-agonist-dependent lipolytic responses and characterization of p-adrenergic binding sites on human fat cell membranes with highly selective β3-agonists. J Lipid Res 29: 587–601.PubMedGoogle Scholar
  23. 23.
    Krieif S, Lonnqvist F, Raimbault S et al. (1993) Tissue distribution of β1-adrenergic receptor mRNA in man. J Clin Invest 91: 344–349.CrossRefGoogle Scholar
  24. 24.
    Chaudhry A, Lahners KN, Granneman JG (1992) Perinatal changes in the coupling of pand β1- and β3-adrenergic receptors in brown fat adenylyl cyclase. J Pharmacol Exp Ther 261: 633–637.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • G. Vauquelin

There are no affiliations available

Personalised recommendations